Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Rachel H. Rose, Armin Sepp, Felix Stader, Katherine L. Gill, Cong Liu & Iain Gardner. (2022) Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities. Xenobiotica 52:8, pages 840-854.
Read now
Read now
Adam J. Dourson, Adam Willits, Namrata G.R. Raut, Leena Kader, Erin Young, Michael P. Jankowski & Vidya Chidambaran. (2022) Genetic and epigenetic mechanisms influencing acute to chronic postsurgical pain transitions in pediatrics: Preclinical to clinical evidence. Canadian Journal of Pain 6:2, pages 85-107.
Read now
Read now
Eva Germovsek, Ming Cheng & Craig Giragossian. (2021) Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. mAbs 13:1.
Read now
Read now
Anne Smits, Pieter De Cock, An Vermeulen & Karel Allegaert. (2019) Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opinion on Drug Metabolism & Toxicology 15:1, pages 25-34.
Read now
Read now
Articles from other publishers (21)
A. Nassar-Sheikh Rashid, D. Schonenberg-Meinema, S. C. Bergkamp, S. Bakhlakh, A. de Vries, T. Rispens, T. W. Kuijpers, G. Wolbink & J. M. van den Berg. (2021) Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). Pediatric Rheumatology 19:1.
Crossref
Crossref
Tatjana Welzel, Carolyn Winskill, Nancy Zhang, Andreas Woerner & Marc Pfister. (2021) Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. Pediatric Rheumatology 19:1.
Crossref
Crossref
Miguel Nogueira, Amy S. Paller & Tiago Torres. (2021) Targeted Therapy for Pediatric Psoriasis. Pediatric Drugs 23:3, pages 203-212.
Crossref
Crossref
Kathleen M. Stephanos & Lindsey Picard. 2021. Oncologic Emergency Medicine. Oncologic Emergency Medicine
471
479
.
Jerry Li, Mina Nikanjam, Coleen K. Cunningham, Elizabeth J. McFarland, Emily E. Coates, Katherine V. Houser, Bob C. Lin, Adrian B. McDermott, Britta Flach, Lucio Gama, Richard A. Koup, Barney S. Graham, John R. Mascola, Julie E. Ledgerwood & Edmund V. Capparelli. (2020) Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clinical Pharmacology & Therapeutics 109:1, pages 184-192.
Crossref
Crossref
Xian Pan, Felix Stader, Khaled Abduljalil, Katherine L. Gill, Trevor N. Johnson, Iain Gardner & Masoud Jamei. (2020) Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. The AAPS Journal 22:4.
Crossref
Crossref
Laurens F.M. Verscheijden, Jan B. Koenderink, Trevor N. Johnson, Saskia N. de Wildt & Frans G.M. Russel. (2020) Physiologically-based pharmacokinetic models for children: Starting to reach maturation?. Pharmacology & Therapeutics 211, pages 107541.
Crossref
Crossref
Amina Bensalem & David Ternant. (2020) Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. Clinical Pharmacokinetics 59:7, pages 857-874.
Crossref
Crossref
Sumit Basu, Yi Ting (Kayla) Lien, Valvanera Vozmediano, Jan-Frederik Schlender, Thomas Eissing, Stephan Schmidt & Christoph Niederalt. (2020) Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. Frontiers in Pharmacology 11.
Crossref
Crossref
Zaid H. Temrikar, Satyendra Suryawanshi & Bernd Meibohm. (2020) Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients. Pediatric Drugs 22:2, pages 199-216.
Crossref
Crossref
Paul R. V. Malik & Andrea N. Edginton. (2019) Integration of Ontogeny Into a Physiologically Based Pharmacokinetic Model for Monoclonal Antibodies in Premature Infants. The Journal of Clinical Pharmacology 60:4, pages 466-476.
Crossref
Crossref
William D Renton & Athimalaipet V Ramanan. (2020) Better pharmacologic data the key to optimizing biological therapies in children. Rheumatology 59:2, pages 271-272.
Crossref
Crossref
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin & Sandhya Girish. (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Navita L. Mallalieu, Sunethra Wimalasundera, Joy C. Hsu, Wendy Douglass, Chris Wells, Inmaculada Calvo Penades, Ruben Cuttica, Hans-Iko Huppertz, Rik Joos, Yukiko Kimura, Diana Milojevic, Margalit Rosenkranz, Kenneth Schikler, Tamas Constantin & Carine Wouters. (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology 17:1.
Crossref
Crossref
David Ternant & Stéphanie Chhun. (2020) Variabilité pharmacocinétique des anticorps thérapeutiques. médecine/sciences 35:12, pages 1130-1136.
Crossref
Crossref
Paul R. V. Malik & Andrea N. Edginton. (2019) Physiologically‐Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients. CPT: Pharmacometrics & Systems Pharmacology 8:11, pages 835-844.
Crossref
Crossref
Tim Niehues & Tuba Turul Özgür. (2019) The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents. Deutsches Ärzteblatt international.
Crossref
Crossref
Ibrahim Ince, Juri Solodenko, Sebastian Frechen, André Dallmann, Christoph Niederalt, Jan Schlender, Rolf Burghaus, Jörg Lippert & Stefan Willmann. (2019) Predictive Pediatric Modeling and Simulation Using Ontogeny Information. The Journal of Clinical Pharmacology 59:S1.
Crossref
Crossref
Xiaomei I. Liu, André Dallmann, Yow‐Ming Wang, Dionna J. Green, Janelle M. Burnham, Beatrice Chiang, Perry Wu, Mark Sheng, Kelley Lu, John N. Anker & Gilbert J. Burckart. (2019) Monoclonal Antibodies and Fc‐Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. The Journal of Clinical Pharmacology 59:8, pages 1130-1143.
Crossref
Crossref
Nina Hanke, Claudia Kunz, Meinolf Thiemann, Harald Fricke & Thorsten Lehr. (2019) Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients. Pharmaceutics 11:4, pages 152.
Crossref
Crossref
Christina L. Szperka, Juliana VanderPluym, Serena L. Orr, Christopher B. Oakley, William Qubty, Irene Patniyot, Ana Marissa Lagman-Bartolome, Cynthia Morris, Jessica Gautreaux, M. Cristina Victorio, Suzanne Hagler, Sona Narula, Meghan S. Candee, Catalina Cleves-Bayon, Rashmi Rao, Robert H. Fryer, Alma R. Bicknese, Marcy Yonker, Andrew D. Hershey, Scott W. Powers, Peter J. Goadsby & Amy A. Gelfand. (2018) Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache: The Journal of Head and Face Pain 58:10, pages 1658-1669.
Crossref
Crossref